Health News | Three-medicine Combination Therapy is Beneficial in Patients with High-risk CLL: Study
Get latest articles and stories on Health at LatestLY. According to a new, phase 2 clinical trial led by Dana-Farber Cancer Institute doctors, a three-medicine combination that drove chronic lymphocytic leukaemia (CLL) patients into profound remissions in a clinical study is very beneficial in patients with high-risk variants of the disease.
New Orleans [US], December 11 (ANI): According to a new phase 2 clinical trial led by Dana-Farber Cancer Institute doctors, a three-medicine combination that drove chronic lymphocytic leukaemia (CLL) patients into profound remissions in a clinical study is very beneficial in patients with high-risk variants of the disease.
The initial cohort of the trial, which included patients with any subtype of CLL, found that a regimen of acalabrutinib, venetoclax, and obinutuzumab produced deep remissions in 89% of participants. The new cohort, which exclusively included patients with high-risk CLL, found a similar deep-remission rate of 83%.
The study's lead author, Christine Ryan, MD, of Dana-Farber, will present the findings at the American Society of Hematology (ASH) Annual Meeting.
The trial, conducted at Dana-Farber, Beth Israel Deaconess Medical Center, Stamford (Conn.) Hospital, and Lifespan Health System, in Rhode Island, involves 68 patients with previously untreated CLL, 41 of whom have a mutation and/or deletion in the TP53 gene in their tumor cells -- an abnormality associated with an aggressive form of the disease.
Also Read | Jammu and Kashmir: Two Children Killed Due to Suspected 'Hepatitis Outbreak' in Anantnag.
Patients are treated with acalabrutinib (a targeted drug), obinutuzumab (an antibody therapy), and venetoclax (a targeted agent) on a specified schedule that can continue for up to 16 cycles.
At a median follow-up of 35 months, 83% of the high-risk patients had undetectable minimal residual disease (MRD) -- no detectable CLL cells per 100,000 white blood cells -- in their bone marrow.
And, 45% had the deepest measurable response to the treatment: complete remission and undetectable MRD in the bone marrow.
Overall, the treatment was well-tolerated, researchers found, with low rates of cardiovascular problems and infections.
After nearly three years of follow-up, 93 per cent of the trial participants were alive with no advance of their disease. The study has in part supported the development of a large, phase III trial of the regimen for patients with CLL without high-risk disease that has the potential to lead to FDA approval of the regimen.
"Our data provide foundational support for using this triplet therapy in patients with high-risk CLL patients," says study senior author and principal investigator Matthew Davids, MD, MMSC, of Dana-Farber. (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)